Meta-analysis Of Diagnostic Anti-GP210 Antibody And Anti-SP100 Antibody Detection For Primary Biliary Cirrhosis

Background and Objective: Primary biliary cirrhosis(PBC) is a chronic, progressive autoimmune disease that is characterized by non-suppurative inflammation of small bile ducts, and the destruction and fibrosis of liver cells, and may progress from cirrhosis to hepatic failure. To conduct a systematic review of studies assessing the association of anti-GP210 antibody and anti-SP100 antibody with diagnosis of PBC using meta-analysis.Methods: Five research literature databases, including the Cochrane Library, MEDLINE, VIP, CNKI and Wan Fang, were searched for studies of anti-GP210 antibody and anti-SP100 antibody in diagnosis of PBC. Meta-disc statistical software was used for analysis.Results: The meta-analysis included a total of 25 studies on anti-GP210 antibody and 21 studies on anti-SP100 antibody. The diagnostic odds ratio, sensitivity, and specificity of anti-GP210 antibody for diagnosis of PBC were 24.854(11.957–51.660), 0.272(0.257–0.288), and 0.985(0.982–0.988), respectively, and for anti-SP100 antibody they were 9.133(4.739–17.600), 0.231(0.213–0.249), and 0.977(0.973–0.981), respectively.Conclusions: Both anti-GP210 antibody and anti-SP100 antibody show high specificity but low sensitivity in diagnosis of PBC.